



Glenmark Pharmaceuticals Europe Limited

Publication date: 31 January 2025

Commitment to achieving Net Zero

Glenmark Pharmaceuticals Europe Limited are committed to achieving Net Zero Carbon emissions by 2050, at the latest.

This Glenmark Pharmaceuticals Europe Limited Carbon Reduction Plan can also be accessed [here](#)

The Glenmark Pharmaceuticals Limited (Parent) Environmental, Social, and Governance (ESG) factbook offers a supplementary collection of pertinent and material information and it should be referred to alongside our integrated annual report FY 2024 for a comprehensive understanding of our global sustainability practices, which can be accessed [here](#)

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: YE 31 March 2024 Glenmark Pharmaceuticals Europe Limited

Additional details relating to the Baseline Emissions calculations.

During April 2024 Glenmark Pharmaceuticals Limited and its UK subsidiary Glenmark Pharmaceuticals Europe Limited set its ambition to be Net Zero by 2050.

The 2023 baseline year emissions reported below are the Scope 1, Scope 2, and selected Scope 3 emissions for Glenmark Pharmaceuticals Europe Limited only.

EMISSIONS	TOTAL (tCO₂e)		
Scope 1	2.29		
Scope 2	53.88		
Scope 3 (Included Sources)	2,607.54		
	Our Scope 3 emissions subset is indicated below.		
	3: UK grid electricity T&D	Building:	4.61
	4: Upstream transportation and distribution	Transport & Distribution	1,936.04
	5: Waste generated in operations	Waste water	0.15
	5: Waste generated in operations	Commercial waste	0.09
	6: Business travel	Hotel stay	11.65
	6: Business travel	Air travel	432.49
	6: Business travel	Land travel - Taxis	3.04
	6: Business travel	Land travel - Grey and managed fleet	46.91
	7: Employee commuting	Commuting	54.11
	7: Employee commuting	Homeworking	12.05
	9: Downstream transportation and distribution	Transport & Distribution	106.40
Total Emissions - tCO₂e	2,663.71		

Current Emissions Reporting

Reporting Year: YE 31 March 2024 Glenmark Pharmaceuticals Europe Limited			
EMISSIONS	TOTAL (tCO ₂ e)		
Scope 1	2.29		
Scope 2	53.88		
Scope 3 (Included Sources)	2,607.54		
	Our Scope 3 emissions subset is indicated below.		
	3: UK grid electricity T&D	Building:	4.61
	4: Upstream transportation and distribution	Transport & Distribution	1,936.04
	5: Waste generated in operations	Waste water	0.15
	5: Waste generated in operations	Commercial waste	0.09
	6: Business travel	Hotel stay	11.65
	6: Business travel	Air travel	432.49
	6: Business travel	Land travel - Taxis	3.04
	6: Business travel	Land travel - Grey and managed fleet	46.91
	7: Employee commuting	Commuting	54.11
	7: Employee commuting	Homeworking	12.05
	9: Downstream transportation and distribution	Transport & Distribution	106.40
Total Emissions - tCO₂e	2,663.71		

Emissions reduction targets

Glenmark Pharmaceuticals Europe Limited set its ambition to achieve Net Zero GHG emissions by 2050 at the latest, as indicated below.

- Net Zero emissions across our UK operations by 2050 at the latest (Scope 1 and Scope 2)
- Net Zero emissions across our full value chain by 2050 at the latest (Scope 3)


To track our progress to achieving Net Zero, Glenmark Pharmaceuticals Europe Limited have adopted the following near-term targets.

- Scope 1 and Scope 2: 54.6% reduction by 2033 vs 2023 baseline year, based on the limiting warming to 1.5°C aligned pathway.
 - Scope 1 & 2 = 56.2 tonnes CO₂e in 2023 to 25.5 tonnes CO₂e in 2033
- Scope 3: 32.5% reduction by 2033 vs 2023 baseline year, based on the limiting global warming to well-below 2°C aligned pathway.
 - Scope 3 = 2,608 tonnes CO₂e in 2023 to 1,760 tonnes CO₂e in 2033.

Our target setting method is based on the absolute contraction approach of science-based target setting.

The graph below shows our projected near-term carbon reduction pathway, and our progress against these targets will be reported from 2024 onward. We report on all Scope 1, Scope 2 and a sub-set of Scope 3 emissions as indicated in the above baseline reporting.

Projected near-term carbon reduction pathway:



	2023 Baseline	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Target Scope 1 & 2 - tCO2e	56.17	53.10	50.04	46.97	43.90	40.84	37.77	34.70	31.63	28.57	25.50
Actual Scope 1 & 2 - tCO2e	56.17										
Target Scope 3 - tCO2e	2,607.54	2,523	2,438	2,353	2,269	2,184	2,099	2,014	1,930	1,845	1,760
Actual Scope 3 - tCO2e	2,607.54										
Total in-scope emissions - tCO2e	2,663.71										

Carbon Reduction Projects

Completed Carbon Reduction Initiatives

The following environmental management measures and projects have been completed.

Currently, 82% of our manufacturing sites globally are certified to ISO 14001 – Environmental Management System certified.

Glenmark Pharmaceuticals Limited established a global ESG (Environmental, Social and Governance) sub-committee focused on establishing a comprehensive program to optimise our ESG efforts and have published their first ESG factbook during 2024.

In partnership with our Managing Agent, the Croxley Green Business Park has maintained a Zero Waste to Landfill status since 2011.

Glenmark Pharmaceuticals Europe Limited has implemented a Hybrid working policy in the UK, directly decreasing the energy consumption and associated emissions required for employees to commute to and from work.

Going forward, we will be investigating and implementing further carbon reduction initiatives and projects to support our Net Zero drive, such as:

2025:

- Review the recommendations from our ESOS Phase 3 report and associated ESOS Phase 3 Action Plan.
- Review and update key business policies and procedures to ensure that business practices are aligned and supportive of our Net Zero commitment.
- Review and optimise freighting channels for imported products to the UK.
- Optimise road transportation routes within the UK.
- Engage the Managing Agent to source a 100% renewable electricity supply contract.

2026 onward:

- Implement a Green Lease for our office.
- Expand Scope 3 GHG inventory to cover all 15 Scope 3 categories.
- Develop a supplier engagement programme to drive Scope 3 emission reduction from our supply chain.
- Transition owned and/or controlled fleet to hybrid/battery electric vehicles.
- Develop costed Net Zero Carbon (NZC) business plans.
- Develop a NZC pathway inclusive of milestones.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

The environmental measures and near-term targets set out above will be applied in the performance of the contract by Glenmark Pharmaceuticals Europe Limited.

This Carbon Reduction Plan was approved by the board of directors of Glenmark Pharmaceuticals Europe Limited on 31 January 2025.

Director:

Signature:

¹<https://ghgprotocol.org/corporate-standard>

²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³<https://ghgprotocol.org/standards/scope-3-standard>